Cargando…

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients

Detalles Bibliográficos
Autores principales:	Rosati, Gerardo, Aprile, Giuseppe, Basile, Debora, Avallone, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960908/ https://www.ncbi.nlm.nih.gov/pubmed/33738249 http://dx.doi.org/10.3389/fonc.2021.602596

Ejemplares similares

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
por: Damato, Angela, et al.
Publicado: (2021)

HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study
por: Fraga, Teresa, et al.
Publicado: (2023)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
por: Zelli, Veronica, et al.
Publicado: (2022)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
por: Grassi, Elisa, et al.
Publicado: (2021)

Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives
por: Takeda, Hiroyuki, et al.
Publicado: (2021)

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2020)

Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
por: Rachiglio, Anna Maria, et al.
Publicado: (2022)

Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
por: Klein-Scory, Susanne, et al.
Publicado: (2020)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients
por: Salvatore, Lisa, et al.
Publicado: (2023)

Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients
por: Guan, Wen-Long, et al.
Publicado: (2020)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2016)

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
por: Aasebø, Kristine, et al.
Publicado: (2020)

Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
por: Martins, Diana, et al.
Publicado: (2022)

BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
por: Li, Zi-Nan, et al.
Publicado: (2020)

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
por: Yan, Ningning, et al.
Publicado: (2022)

Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report
por: De Stefano, Alfonso, et al.
Publicado: (2023)

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
por: Martini, Giulia, et al.
Publicado: (2023)

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis
por: Bylsma, Lauren C., et al.
Publicado: (2019)

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
por: Parisi, Alessandro, et al.
Publicado: (2021)

Exploring Better Strategies for RAS Mutation-Associated EGFR-Targeted Resistance in Colorectal Cancer: From the Perspective of Cancer Community Ecology
por: Wang, Xiaojie, et al.
Publicado: (2021)

Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Aged at Least 75 Years: A Post-Hoc Subgroup Analysis of Three Phase II Trials
por: Rosati, Gerardo, et al.
Publicado: (2019)

Perspectives on Immunotherapy of Metastatic Colorectal Cancer
por: Dai, Yongjiu, et al.
Publicado: (2021)

Liquid Biopsies in Progressing Metastatic Colorectal Cancer- Application and their Therapeutic Implications According to the RAS Status
por: Pereira, José, et al.
Publicado: (2020)

The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer
por: Shetty, Omshree, et al.
Publicado: (2022)

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
por: Yao, Jiannan, et al.
Publicado: (2018)

Strategies to tackle RAS-mutated metastatic colorectal cancer
por: Patelli, G., et al.
Publicado: (2021)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
por: Fanelli, Giuseppe Nicolò, et al.
Publicado: (2020)

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study
por: Negru, Serban, et al.
Publicado: (2014)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

BRAF-mutated metastatic colorectal cancer between past and future
por: Cremolini, Chiara, et al.
Publicado: (2015)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1m45o7c5peee0qef3ieaf235hr